Mp31-15 Evaluating Use of a Genetic Risk Score to Improve Prostate Cancer Risk Stratification in Black Men: A Retrospective Pilot Study

You have accessJournal of UrologyProstate Cancer: Detection & Screening III (MP31)1 May 2024MP31-15 EVALUATING USE OF A GENETIC RISK SCORE TO IMPROVE PROSTATE CANCER RISK STRATIFICATION IN BLACK MEN: A RETROSPECTIVE PILOT STUDY Sean A. Fletcher, Claire M. de la Calle, Guifan Yan, Marta Gielzak, Jianfeng Xu, William B. Isaacs, and Christian P. Pavlovich Sean A. FletcherSean A. Fletcher , Claire M. de la CalleClaire M. de la Calle , Guifan YanGuifan Yan , Marta GielzakMarta Gielzak , Jianfeng XuJianfeng Xu , William B. IsaacsWilliam B. Isaacs , and Christian P. PavlovichChristian P. Pavlovich View All Author Informationhttps://doi.org/10.1097/01.JU.0001008936.35187.0b.15AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Over 280 previously identified single nucleotide polymorphisms (SNPs) can inform a "genetic risk score" (GRS) to predict diagnosis of prostate cancer. Prior research on GRS has largely focused on men of European ancestry, which limits applicability to Black men. Additionally, less is known about the ability of GRS to predict aggressiveness of prostate cancer. Therefore, our objective was to evaluate the ability of an ancestry-specific GRS to predict prostate cancer grade in a cohort of Black men. METHODS: We identified Black men enrolled in our institutional biorepository who underwent prostate biopsy (2011 – 2021) for elevated PSA (2.5-10 ng/mL). White buffy coat samples were retrieved for those who fit inclusion criteria. DNA extraction and sequencing were performed in preparation for GRS analysis using a panel that included 43 African ancestry-specific SNPs. GRS scores were assigned to each patient, with stratification into low (<0.5), intermediate (0.5-1.5), and high-risk groups (>1.5). Clinicopathologic characteristics were recorded for each patient (biopsy Gleason grade, tumor volume, definitive treatment, follow-up). The primary outcome was Gleason grade group (GG) on initial biopsy. RESULTS: We identified 97 patients who fit our selection criteria. Their blood samples were retrieved for DNA extraction and sequencing. Of these, 48 had sufficient DNA available for GRS analysis. At enrollment, median age was 59 (IQR: 49-64) and median PSA was 5.2 ng/mL (4.4-6.8). The majority (61%) had Gleason grade group 2 or higher disease on biopsy. The median GRS value of this cohort was 1.07 (IQR: 0.65 – 1.79). There was no difference in proportion of clinically significant prostate cancer ( >GG2) by GRS risk group (p=0.9; Fisher's exact test). There was also no correlation between raw GRS score and Gleason grade (Figure 1). CONCLUSIONS: In this interim analysis, there was no significant association between GRS and Gleason grade on biopsy in a cohort of Black men. The GRS may be limited in its ability to distinguish indolent from aggressive prostate cancer. Study limitations include small sample size and selection of patients from a large referral center. Future directions include augmenting this pilot data with additional patients from a multi-institutional cohort. Download PPT Source of Funding: AUA Residency Research Award (2022-2023) sponsored by Merck & Co © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e510 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Sean A. Fletcher More articles by this author Claire M. de la Calle More articles by this author Guifan Yan More articles by this author Marta Gielzak More articles by this author Jianfeng Xu More articles by this author William B. Isaacs More articles by this author Christian P. Pavlovich More articles by this author Expand All Advertisement PDF downloadLoading ...